Clopidogrel
11
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (11)
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
The Prevention of Thromboembolic Complications Associated With Coil Embolization
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
PACT (Platelet Activity After Clopidogrel Termination)
Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
VerifyNow French Registry
Cohort Study of Clopidogrel and Proton Pump Inhibitors